Albany, NY -- (SBWIRE) -- 05/06/2014 -- The improving regulatory environment and the increasing foreign direct investment make Mexico's pharmaceutical market more attractive to multinational drugmakers. We project an increase in government healthcare spending to further boost the number of procedures and expand access to medicines in its national health insurance programme.
View Full Report with TOC at: http://www.researchmoz.us/the-pharmaceutical-market-mexico-report.html
However, the potential deceleration of the country's macroeconomic growth may dampen the country's pharmaceutical market prospects. Generic drug competition and counterfeit medicines are also key concerns for multinationals pharmaceutical companies.
Headline Expenditure Projections
Pharmaceuticals: MXN161.45bn (US$12.99bn) in 2011 to MXN175.82bn (US$13.47bn) in 2012; +8.9% in local currency terms and +3.7% in US dollar terms. Forecasts increasefromQ4 12 due tomacroeconomic factors.
Healthcare: MXN872.57bn (US$70.21bn) in 2011 to MXN951.98bn (US$72.95bn) in 2012; +9.1% in local currency terms and +3.9 % in US dollar terms. Forecastsincrease from Q4 12 due tomacroeconomic factors.
Medical devices: MXN52.05bn (US$4.19bn) in 2011 to MXN57.85bn (US$4.43bn) in 2012; +11.1% in local currency terms and +5.9% in US dollar terms. Forecastsincrease from Q4 12 due tomacroeconomic factors.
The Pharmaceutical and Healthcare Risk/Reward Rating (RRR) in Q113 for Mexico remains the same (58.4) as in Q412. Mexico still ranks the fourth out of the 17 Americas markets surveyed in our proprietary regional RRR rating system above Brazil, indicating a more optimistic outlook for Mexican market.
Browse More Reports related to Pharmaceutical: http://www.researchmoz.us/pharmaceutical-market-reports-38.html
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
The Pharmaceutical Market: Australia
The country's health expenditure will continue to increase with the increasingly ageing population and the need for the government to subsidise more drugs to treat chronic, non-communicable disease. Such a rise in expenditure will attract pharmaceutical firms despite the low growth potential in the developed market. However, given the poor fiscal outlook in the general economy, we believe such a generous healthcare system will be unsustainable over the long term and the country will continue look at cost-cutting measures, negatively affecting the earnings of pharmaceutical firms. Browse Full Report with TOC at: http://www.researchmoz.us/the-pharmaceutical-market-australia-report.html
The Pharmaceutical Market: Central America
The political instability and underdeveloped economies in many Central American countries make the region less attractive to multinationals, compared with most neighbouring countries. However, the heavy reliance on imported medicine in the region provides revenue-generating opportunities for generic drugmakers from neighbouring Latin American countries and India. Browse Full Report with TOC at: http://www.researchmoz.us/the-pharmaceutical-market-central-america-report.html
ResearchMoz ( http://www.researchmoz.us/ ) is the one stop online destination to find and buy market research reports. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning.
For More Information Kindly Contact:
Toll Free: 866-997-4948